Travera Early Access Program

The Travera EarlyAccess™ and the Travera RTS™ tests are available as a part of a temporary Early Access Program.

Program Limitations

 

Consider the following limitations and potential risks:

  • We may not receive enough live cells and can’t test the entire panel of 20 drugs.

  • Shipping delays may result in the death of cancer cells. The sample would be rejected.

  • All clinical studies have been promising and the evidence is growing but it’s still preliminary.

  • Our catalog includes over 100 drugs but does not yet include all FDA-approved cancer drugs.

  • We do not address sarcomas and lymphomas yet.

  • We do not test pediatric cancers (for patients under 18 years old).

Please refer to the Support page for further information.